外陰カンジダ症治療の世界市場レポート 2025年

外陰カンジダ症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.5％で14億8,000万米ドルに成長します。予測期間の成長は、ヘルスケア支出の増加、高齢者人口の拡大、慢性疾患の有病率の上昇、新しい抗真菌薬の開発、膣疾患に対する意識の高まりに関連しています。この期間の主な動向としては、技術の進歩、戦略的提携、研究開発投資の増加、革新的な治療オプション、先進治療などが挙げられます。

膣障害に対する認識の高まりは、外陰カンジダ症治療市場の成長を促進すると予想されます。膣障害には、感染症、炎症、刺激、異常なおりものなど、膣に影響を及ぼす疾患が含まれます。このような意識の高まりは、教育の強化、ヘルスケアへのアクセスの改善、女性の健康と幸福の重視の強化によって後押しされています。外陰膣カンジダ症の治療は、かゆみ、炎症、異常なおりものなどの症状を緩和し、膣内細菌叢を回復させ、感染症の再発を予防し、膣の全体的な健康と快適さを改善することによって患者を支援します。例えば、2024年10月、オーストラリアに本部を置く政府機関であるCancer Australiaは、2022年に新たに診断された膣がんの症例は123例と推定され、30人が死亡したと報告しました。その結果、膣疾患に対する意識の高まりが外陰カンジダ症治療市場の拡大に寄与しています。

外陰カンジダ症治療市場の主要企業は、治療効果と患者の利便性を高めるため、経口薬や非アゾール薬などの新規医薬品に注力しています。経口・非アゾール薬とは、経口で服用する抗真菌薬で、アゾール系に属さないものを指し、真菌感染症の代替治療薬となります。例えば、2022年12月、米国のバイオテクノロジー企業であるScynexis Inc.は、再発性外陰カンジダ症（RVVC）の発症率を低下させる経口・非アゾール薬であるBREXAFEMME（イブレキサファンガープ錠）を発表しました。本剤は、米国食品医薬品局（FDA）より、外陰カンジダ症（VVC）の治療とVVCの再発抑制の両方の効能・効果で初めて承認された唯一の治療薬です。この承認により、ブレキサフェムは再発性感染症患者に対する重要な治療選択肢として確立され、RVVCを管理する新たなアプローチを提供することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界外陰カンジダ症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の外陰カンジダ症治療市場：成長率分析
• 世界の外陰カンジダ症治療市場の実績：規模と成長, 2019-2024
• 世界の外陰カンジダ症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界外陰カンジダ症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の外陰カンジダ症治療市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クロトリマゾール
• ナイスタチン
• フルコナゾール
• ケトコナゾール
• テルビナフィン
• テルコナゾール
• その他の薬物クラス
• 世界の外陰カンジダ症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• トピック
• 世界の外陰カンジダ症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の外陰カンジダ症治療市場クロトリマゾールの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 市販薬（OTC）
• 処方薬
• 世界の外陰カンジダ症治療市場ナイスタチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤療法
• 併用療法
• 世界の外陰カンジダ症治療市場フルコナゾールの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単回投与療法
• 多回投与療法
• 世界の外陰カンジダ症治療市場ケトコナゾールの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 短期治療
• 長期治療
• 世界の外陰カンジダ症治療市場テルビナフィンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身治療
• 局所治療
• 世界の外陰カンジダ症治療市場テルコナゾールの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低用量療法
• 高用量療法
• 世界の外陰カンジダ症治療市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アゾール系抗真菌薬
• ポリエン系抗真菌剤
• 新しい治療法

第7章 地域別・国別分析

• 世界の外陰カンジダ症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の外陰カンジダ症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 外陰カンジダ症治療市場：競合情勢
• 外陰カンジダ症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Zydus Lifesciences
• Novartis Pharmaceuticals Inc.
• Glenmark Pharmaceuticals Ltd.
• Shandong Boyuan Pharmaceutical
• Taro Pharmaceuticals Industries Ltd.
• Accord Healthcare Ltd.
• Incepta Pharmaceuticals Ltd.
• Cosette Pharmaceuticals Inc.
• Crescent Pharma Ltd.
• Bhumi Pharmaceuticals
• Cidara Therapeutics Inc.
• Avet Pharmaceuticals Inc.
• Austell Pharmaceuticals Ltd.
• Laboratoire Riva Inc.
• Cadila Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 外陰カンジダ症治療市場2029：新たな機会を提供する国
• 外陰カンジダ症治療市場2029：新たな機会を提供するセグメント
• 外陰カンジダ症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vulvovaginal candidiasis treatment involves the medical management of a common fungal infection caused by Candida species, which affects the vaginal region. The goal of treatment is to ease symptoms such as itching, burning, and unusual discharge. These treatments primarily focus on reducing discomfort, restoring balance, and preventing the infection from recurring.

The primary medications used for vulvovaginal candidiasis include clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others. Clotrimazole, a widely used antifungal drug, is commonly prescribed for this condition. It can be administered orally, intravenously, or topically and is available through hospital pharmacies, retail pharmacies, and online pharmacies.

The vulvovaginal candidiasis treatment market research report is one of a series of new reports from The Business Research Company that provides vulvovaginal candidiasis treatment market statistics, including vulvovaginal candidiasis treatment industry global market size, regional shares, competitors with a vulvovaginal candidiasis treatment market share, detailed vulvovaginal candidiasis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the vulvovaginal candidiasis treatment industry. This vulvovaginal candidiasis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vulvovaginal candidiasis treatment market size has grown strongly in recent years. It will grow from $1.13 billion in 2024 to $1.19 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the rising prevalence of vulvovaginal candidiasis, the expansion of insurance coverage, the increasing number of clinical trials, advancements in research and development activities, and the growing use of broad-spectrum antibiotics.

The vulvovaginal candidiasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period can be linked to rising healthcare expenditures, an expanding geriatric population, a higher prevalence of chronic diseases, the development of new antifungal medications, and increasing awareness of vaginal disorders. Key trends during this period include technological advancements, strategic collaborations, increased investment in research and development, innovative treatment options, and advanced therapies.

The increasing awareness of vaginal disorders is expected to drive the growth of the vulvovaginal candidiasis treatment market. Vaginal disorders encompass conditions that affect the vagina, including infections, inflammation, irritation, and abnormal discharge. This growing awareness is fueled by enhanced education, better healthcare access, and a stronger emphasis on women's health and well-being. Treatments for vulvovaginal candidiasis help patients by relieving symptoms such as itching, irritation, and abnormal discharge, restoring the vaginal microbiome, preventing recurrent infections, and improving overall vaginal health and comfort. For example, in October 2024, Cancer Australia, a government agency based in Australia, reported an estimated 123 new cases of vaginal cancer diagnosed in 2022, with 30 fatalities. As a result, the rising awareness of vaginal disorders is contributing to the expansion of the vulvovaginal candidiasis treatment market.

Leading companies in the vulvovaginal candidiasis treatment market are focusing on novel pharmaceuticals, such as oral and non-azole medications, to enhance treatment effectiveness and patient convenience. Oral and non-azole medication refers to antifungal drugs that are taken orally and do not belong to the azole class, providing an alternative treatment for fungal infections. For instance, in December 2022, Scynexis Inc., a US-based biotechnology company, introduced BREXAFEMME (ibrexafungerp tablets), an oral and non-azole medication, to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC). This medication was approved by the Food and Drug Administration (FDA), a US-based government agency, and became the first and only FDA-approved therapy for both treating vulvovaginal candidiasis (VVC) and lowering the incidence of recurrent VVC. This approval establishes BREXAFEMME as a crucial treatment option for patients with recurrent infections, offering a new approach to managing RVVC.

In February 2024, Mycovia Pharmaceuticals Inc., a US-based pharmaceutical company, partnered with Jiangsu Hengrui Pharmaceuticals Co. Ltd. to introduce VIVJOA (oteseconazole) capsules in China for the treatment of severe vulvovaginal candidiasis (VVC). Through this collaboration, Mycovia Pharmaceuticals Inc. and Jiangsu Hengrui Pharmaceuticals Co. Ltd. seek to provide an effective solution for severe vulvovaginal candidiasis, addressing patients' unmet medical needs and expanding therapeutic options for long-term fungal infection management. Jiangsu Hengrui Pharmaceuticals Co. Ltd. is a China-based company that specializes in treatments for vulvovaginal candidiasis.

Major players in the vulvovaginal candidiasis treatment market are Pfizer Inc., Bayer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences, Novartis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Shandong Boyuan Pharmaceutical, Taro Pharmaceuticals Industries Ltd., Accord Healthcare Ltd., Incepta Pharmaceuticals Ltd., Cosette Pharmaceuticals Inc., Crescent Pharma Ltd., Bhumi Pharmaceuticals, Cidara Therapeutics Inc., Avet Pharmaceuticals Inc., Austell Pharmaceuticals Ltd., Laboratoire Riva Inc., Cadila Pharmaceuticals.

North America was the largest region in the vulvovaginal candidiasis treatment market in 2024. The regions covered in vulvovaginal candidiasis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vulvovaginal candidiasis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vulvovaginal candidiasis treatment market consists of sales of antifungal creams, oral antifungal capsules, suppositories, vaginal gels, pessaries, and non-azole medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vulvovaginal Candidiasis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vulvovaginal candidiasis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vulvovaginal candidiasis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vulvovaginal candidiasis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Clotrimazole; Nystatin; Fluconazole; Ketoconazole; Terbinafine; Terconazole; Other Drug Classes
• 2) By Route Of Administration: Oral; Intravenous; Topical
• 3) By Distribution Channel: Hospital Pharmacy ; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Clotrimazole: Over-the-Counter (OTC) Medications; Prescription Medications
• 2) By Nystatin: Monotherapy; Combination Therapy
• 3) By Fluconazole: Single-Dose Therapy; Multi-Dose Therapy
• 4) By Ketoconazole: Short-Term Treatment; Long-Term Treatment
• 5) By Terbinafine: Systemic Treatment; Topical Treatment
• 6) By Terconazole: Low-Dose Therapy; High-Dose Therapy
• 7) By Other Drug Classes: Azole Antifungals; Polyene Antifungals; Novel Therapeutics
• Companies Mentioned: Pfizer Inc.; Bayer Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Limited; Cipla Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vulvovaginal Candidiasis Treatment Market Characteristics

3. Vulvovaginal Candidiasis Treatment Market Trends And Strategies

4. Vulvovaginal Candidiasis Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vulvovaginal Candidiasis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vulvovaginal Candidiasis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vulvovaginal Candidiasis Treatment Market Growth Rate Analysis
• 5.4. Global Vulvovaginal Candidiasis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vulvovaginal Candidiasis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vulvovaginal Candidiasis Treatment Total Addressable Market (TAM)

6. Vulvovaginal Candidiasis Treatment Market Segmentation

• 6.1. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Other Drug Classes
• 6.2. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Topical
• 6.3. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Clotrimazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Over-the-Counter (OTC) Medications
• Prescription Medications
• 6.5. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Nystatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.6. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Fluconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Therapy
• Multi-Dose Therapy
• 6.7. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Ketoconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-Term Treatment
• Long-Term Treatment
• 6.8. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terbinafine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Treatment
• Topical Treatment
• 6.9. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Dose Therapy
• High-Dose Therapy
• 6.10. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azole Antifungals
• Polyene Antifungals
• Novel Therapeutics

7. Vulvovaginal Candidiasis Treatment Market Regional And Country Analysis

• 7.1. Global Vulvovaginal Candidiasis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vulvovaginal Candidiasis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vulvovaginal Candidiasis Treatment Market

• 8.1. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vulvovaginal Candidiasis Treatment Market

• 9.1. China Vulvovaginal Candidiasis Treatment Market Overview
• 9.2. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vulvovaginal Candidiasis Treatment Market

• 10.1. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vulvovaginal Candidiasis Treatment Market

• 11.1. Japan Vulvovaginal Candidiasis Treatment Market Overview
• 11.2. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vulvovaginal Candidiasis Treatment Market

• 12.1. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vulvovaginal Candidiasis Treatment Market

• 13.1. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vulvovaginal Candidiasis Treatment Market

• 14.1. South Korea Vulvovaginal Candidiasis Treatment Market Overview
• 14.2. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vulvovaginal Candidiasis Treatment Market

• 15.1. Western Europe Vulvovaginal Candidiasis Treatment Market Overview
• 15.2. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vulvovaginal Candidiasis Treatment Market

• 16.1. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vulvovaginal Candidiasis Treatment Market

• 17.1. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vulvovaginal Candidiasis Treatment Market

• 18.1. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vulvovaginal Candidiasis Treatment Market

• 19.1. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vulvovaginal Candidiasis Treatment Market

• 20.1. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vulvovaginal Candidiasis Treatment Market

• 21.1. Eastern Europe Vulvovaginal Candidiasis Treatment Market Overview
• 21.2. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vulvovaginal Candidiasis Treatment Market

• 22.1. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vulvovaginal Candidiasis Treatment Market

• 23.1. North America Vulvovaginal Candidiasis Treatment Market Overview
• 23.2. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vulvovaginal Candidiasis Treatment Market

• 24.1. USA Vulvovaginal Candidiasis Treatment Market Overview
• 24.2. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vulvovaginal Candidiasis Treatment Market

• 25.1. Canada Vulvovaginal Candidiasis Treatment Market Overview
• 25.2. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vulvovaginal Candidiasis Treatment Market

• 26.1. South America Vulvovaginal Candidiasis Treatment Market Overview
• 26.2. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vulvovaginal Candidiasis Treatment Market

• 27.1. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vulvovaginal Candidiasis Treatment Market

• 28.1. Middle East Vulvovaginal Candidiasis Treatment Market Overview
• 28.2. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vulvovaginal Candidiasis Treatment Market

• 29.1. Africa Vulvovaginal Candidiasis Treatment Market Overview
• 29.2. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vulvovaginal Candidiasis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Vulvovaginal Candidiasis Treatment Market Competitive Landscape
• 30.2. Vulvovaginal Candidiasis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Dr. Reddy's Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis

31. Vulvovaginal Candidiasis Treatment Market Other Major And Innovative Companies

• 31.1. Zydus Lifesciences
• 31.2. Novartis Pharmaceuticals Inc.
• 31.3. Glenmark Pharmaceuticals Ltd.
• 31.4. Shandong Boyuan Pharmaceutical
• 31.5. Taro Pharmaceuticals Industries Ltd.
• 31.6. Accord Healthcare Ltd.
• 31.7. Incepta Pharmaceuticals Ltd.
• 31.8. Cosette Pharmaceuticals Inc.
• 31.9. Crescent Pharma Ltd.
• 31.10. Bhumi Pharmaceuticals
• 31.11. Cidara Therapeutics Inc.
• 31.12. Avet Pharmaceuticals Inc.
• 31.13. Austell Pharmaceuticals Ltd.
• 31.14. Laboratoire Riva Inc.
• 31.15. Cadila Pharmaceuticals

32. Global Vulvovaginal Candidiasis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vulvovaginal Candidiasis Treatment Market

34. Recent Developments In The Vulvovaginal Candidiasis Treatment Market

35. Vulvovaginal Candidiasis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Vulvovaginal Candidiasis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vulvovaginal Candidiasis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vulvovaginal Candidiasis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer